Palvella Therapeutics, Inc.
PVLA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.4B
Close$
$5.10
95.6% downside
Current Fair Value
95.6% downsideOvervalued by 95.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.40 Billion |
|---|---|
| Enterprise Value | $1.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.71 |
| Beta | -0.12 |
| Outstanding Shares | 13,085,271 |
Return
| Return on Equity | -21.22% |
|---|---|
| Return on Assets | -18.69% |
| Return on Invested Capital | -8.17% |
Valuation & Multiples
| P/E Ratio | -31.44 |
|---|---|
| PEG | -33.94 |
| Price to Sales | - |
| Price to Book Ratio | 6.79 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -57.49 |
| Enterprise Value to Net Income | -25 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.90
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-1.16
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2681▼ 23.86% |
|---|---|
| Total Calls | 424,400▲ 119.67% |
| Total Puts | 113,800▲ 16.24% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 117.39%▲ 29.18% |
|---|---|
| Total Invested | $1.64B▲ 60.49% |
| Investors Holding | 190▲ 43.00% |
ESG Score
No data
About Palvella Therapeutics, Inc.
14 employees
CEO: Mr. Wesley H. Kaupinen Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamy...